Ryanodine receptor calcium channels and their partners as drug targets

Biochemical Pharmacology

Volumn 79, Issue 11, 2010, Pages 1535-1543

  Mackrill, John J ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Calcium channel; Disease; Drug target; Interacting protein; Ryanodine receptor

Indexed keywords

4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; CAFFEINE; CHLOROCRESOL; DANTROLENE; DOXORUBICIN; PROCAINE; RAPAMYCIN; RUTHENIUM RED; RYANODINE; RYANODINE RECEPTOR; TACROLIMUS; TETRACAINE;

CELLULAR DISTRIBUTION; CHANNEL GATING; COMPLEX FORMATION; DRUG RECEPTOR BINDING; DRUG TARGETING; ENDOPLASMIC RETICULUM; EPILEPSY; EXCITATION CONTRACTION COUPLING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOCATION; GENE MUTATION; GENE TARGETING; HEART; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; MALIGNANT HYPERTHERMIA; MYOPATHY; NEOPLASM; NERVE DEGENERATION; NONHUMAN; NOTE; PAIN; PRIORITY JOURNAL; PROTEIN MODIFICATION; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; UPREGULATION;

ANIMALS; CALCIUM CHANNEL AGONISTS; CALCIUM CHANNEL BLOCKERS; DRUG DELIVERY SYSTEMS; HUMANS; PROTEIN BINDING; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 77950073429     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.01.014     Document Type: Note

References (75)

1. 2+ release channels in evolution. Curr Opin Genet Dev 2000, 10(6):662-667.
2. Guse A.H. Second messenger function and the structure-activity relationship of cyclic adenosine diphosphoribose (cADPR). FEBS J 2005, 272(18):4590-4597.
3. 2+-release channels. Trends Pharmacol Sci 1994, 15(5):145-149.
4. 2+ release channel. J Biol Chem 1987, 262(14):6460-6463.
5. Lai F.A., Erickson H.P., Rousseau E., Liu Q.Y., Meissner G. Purification and reconstitution of the calcium release channel from skeletal muscle. Nature 1988, 331(6154):315-319.
6. Takeshima H., Iino M., Takekura H., Nishi M., Kuno J., Minowa O., et al. Excitation-contraction uncoupling and muscular degeneration in mice lacking functional skeletal muscle ryanodine-receptor gene. Nature 1994, 369(6481):556-559.
7. Inui M., Saito A., Fleischer S. Isolation of the ryanodine receptor from cardiac sarcoplasmic reticulum and identity with the feet structures. J Biol Chem 1987, 262(32):15637-15642.
8. Györke S., Carnes C. Dysregulated sarcoplasmic reticulum calcium release: potential pharmacological target in cardiac disease. Pharmacol Ther 2008, 119(3):340-354.
9. Takeshima H., Komazaki S., Hirose K., Nishi M., Noda T., Iino M. Embryonic lethality and abnormal cardiac myocytes in mice lacking ryanodine receptor type 2. EMBO J 1998, 17(12):3309-3316.
10. Giannini G., Conti A., Mammarella S., Scrobogna M., Sorrentino V. The ryanodine receptor/calcium channel genes are widely and differentially expressed in murine brain and peripheral tissues. J Cell Biol 1995, 128(5):893-904.
11. 2+ release channels in mammalian tissues and cell lines. Biochem J 1997, 327(1):251-258.
12. Galeotti N., Quattrone A., Vivoli E., Norcini M., Bartolini A., Ghelardini C. Different involvement of type 1, 2, and 3 ryanodine receptors in memory processes. Learn Mem 2008, 15(5):315-323.
13. Galeotti N., Vivoli E., Bartolini A., Ghelardini C. A gene-specific cerebral types 1, 2, and 3 RyR protein knockdown induces an antidepressant-like effect in mice. J Neurochem 2008, 106(6):2385-2394.
14. Galeotti N., Quattrone A., Vivoli E., Bartolini A., Ghelardini C. Type 1 and type 3 ryanodine receptors are selectively involved in muscarinic antinociception in mice: an antisense study. Neuroscience 2008, 153(3):814-822.
15. Kouzu Y., Moriya T., Takeshima H., Yoshioka T., Shibata S. Mutant mice lacking ryanodine receptor type 3 exhibit deficits of contextual fear conditioning and activation of calcium/calmodulin-dependent protein kinase II in the hippocampus. Brain Res Mol Brain Res 2000, 76(1):142-150.
16. Matsuo N., Tanda K., Nakanishi K., Yamasaki N., Toyama K., Takao K., et al. Comprehensive behavioral phenotyping of ryanodine receptor type 3 (RyR3) knockout mice: decreased social contact duration in two social interaction tests. Front Behav Neurosci 2009, 3:3.
17. Supnet C., Noonan C., Richard K., Bradley J., Mayne M. Up-regulation of the type 3 ryanodine receptor is neuroprotective in the TgCRND8 mouse model of Alzheimer's disease. J Neurochem. 2010, 112(2):356-365.
18. Berridge M.J., Bootman M.D., Roderick H.L. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 2003, 4(7):517-529.
19. 2+-release channel function. Biochem J 1999, 337(3):345-361.
20. McCarthy T.V., Heffron J.J.A., Mackrill J. Molecular and clinical genetics of RyR1 disorders. Ryanodine receptors: structure, function and dysfunction in clinical disease 2005, 219-228. Springer-Verlag Publishing Inc., New York. X.H.T. Wehrens, A.R. Marks (Eds.).
21. Denborough M. Malignant hyperthermia. Lancet 1998, 352(9134):1131-1136.
22. 2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem 2001, 276(17):13810-13816.
23. Kobayashi S., Bannister M.L., Gangopadhyay J.P., Hamada T., Parness J., Ikemoto N. Dantrolene stabilizes domain interactions within the ryanodine receptor. J Biol Chem 2005, 280(8):6580-6587.
24. López J.R., Cordovez G., Linares N., Allen P.D. Cyclic ADP-ribose induces a larger than normal calcium release in malignant hyperthermia-susceptible skeletal muscle fibers. Pflugers Arch 2000, 440(2):236-242.
25. Xu L., Wang Y., Yamaguchi N., Pasek D.A., Meissner G. Single channel properties of heterotetrameric mutant RyR1 ion channels linked to core myopathies. J Biol Chem 2008, 283(10):6321-6329.
26. Blayney L.M., Lai F.A. Ryanodine receptor-mediated arrhythmias and sudden cardiac death. Pharmacol Ther 2009, 123(2):151-177.
27. Kobayashi S., Yano M., Suetomi T., Ono M., Tateishi H., Mochizuki M., et al. Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. J Am Coll Cardiol 2009, 53(21):1993-2005.
28. Carmody M., Mackrill J.J., Sorrentino V., O'Neill C. FKBP12 associates tightly with the skeletal muscle type 1 ryanodine receptor, but not with other intracellular calcium release channels. FEBS Lett 2001, 505(1):97-102.
29. 2+-release channel in failing human heart. Circulation 2001, 103(June (22)):2739-2744.
30. Mattson M.P. Calcium and neurodegeneration. Aging Cell 2007, 6(3):337-350.
31. 2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest 2008, 118(6):2230-2245.
32. Tester D.J., Spoon D.B., Valdivia H.H., Makielski J.C., Ackerman M.J. Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: a molecular autopsy of 49 medical examiner/coroner's cases. Mayo Clin Proc 2004, 79(11):1380-1384.
33. Tester D.J., Dura M., Carturan E., Reiken S., Wronska A., Marks A.R., et al. A mechanism for sudden infant death syndrome (SIDS): stress-induced leak via ryanodine receptors. Heart Rhythm 2007, 4(6):733-739.
34. Padar S., van Breemen C., Thomas D.W., Uchizono J.A., Livesey J.C., Rahimian R. Differential regulation of calcium homeostasis in adenocarcinoma cell line A549 and its Taxol-resistant subclone. Br J Pharmacol 2004, 142(2):305-316.
35. Abdul M., Ramlal S., Hoosein N. Ryanodine receptor expression correlates with tumor grade in breast cancer. Pathol Oncol Res 2008, 14(2):157-160.
36. Shamash J., Salam A.H., Davies D.C., Williams A., Joel S., Lister T.A. In vitro testing of calcium channel blockers and cytotoxic chemotherapy in B-cell low-grade non-Hodgkin's lymphoma. Br J Cancer 1998, 77(10):1598-1603.
37. Sattelle D.B., Cordova D., Cheek T.R. Insect ryanodine receptors: molecular targets for novel pest control chemicals. Invert Neurosci 2008, 8(3):107-119.
38. Day T.A., Haithcock J., Kimber M., Maule A.G. Functional ryanodine receptor channels in flatworm muscle fibres. Parasitology 2000, 120(4):417-422.
39. Büyükokuroĝlu M.E., Cemek M., Tosun M., Yürümez Y., Baş O., Yavuz Y. Dantrolene may prevent organophosphate-induced oxidative stress and muscle injury. Pestic Biochem Phys 2008, 92(3):156-163.
40. Pessah I.N., Cherednichenko G., Lein P.J. Minding the calcium store: ryanodine receptor activation as a convergent mechanism of PCB toxicity. Pharmacol Ther 2009, [Epub ahead of print].
41. Ta T.A., Pessah I.N. Ryanodine receptor type 1 (RyR1) possessing malignant hyperthermia mutation R615C exhibits heightened sensitivity to dysregulation by non-coplanar 2,2′,3,5′,6-pentachlorobiphenyl (PCB 95). Neurotoxicology 2007, 28(4):770-779.
42. Morisseau C., Merzlikin O., Lin A., He G., Feng W., Padilla I., et al. Toxicology in the fast lane: application of high-throughput bioassays to detect modulation of key enzymes and receptors. Environ Health Perspect 2009, 117(12):1867-1872.
43. Mohaupt M.G., Karas R.H., Babiychuk E.B., Sanchez-Freire V., Monastyrskaya K., Iyer L., et al. Association between statin-associated myopathy and skeletal muscle damage. CMAJ 2009, 181(1-2):E11-E18.
44. Qin J., Zima A.V., Porta M., Blatter L.A., Fill M. Trifluoperazine: a rynodine receptor agonist. Pflugers Arch 2009, 458(4):643-651.
45. Krause T., Gerbershagen M.U., Fiege M., Weisshorn R., Wappler F. Dantrolene-a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004, 59(4):364-373.
46. Dulhunty A.F., Beard N.A., Pouliquin P., Casarotto M.G. Agonists and antagonists of the cardiac ryanodine receptor: potential therapeutic agents?. Pharmacol Ther 2007, 113(2):247-263.
47. Wright N.T., Prosser B.L., Varney K.M., Zimmer D.B., Schneider M.F., Weber D.J. S100A1 and calmodulin compete for the same binding site on ryanodine receptor. J Biol Chem 2008, 283(39):26676-26683.
48. Gellen B., Fernández-Velasco M., Briec F., Vinet L., LeQuang K., Rouet-Benzineb P., et al. Conditional FKBP12.6 overexpression in mouse cardiac myocytes prevents triggered ventricular tachycardia through specific alterations in excitation-contraction coupling. Circulation 2008, 117(14):1778-1786.
49. Milner R.E., Famulski K.S., Michalak M. Calcium binding proteins in the sarcoplasmic/endoplasmic reticulum of muscle and nonmuscle cells. Mol Cell Biochem 1992, 112(1):1-13.
50. Liu N., Priori S.G. Disruption of calcium homeostasis and arrhythmogenesis induced by mutations in the cardiac ryanodine receptor and calsequestrin. Cardiovasc Res 2008, 77(2):293-301.
51. Kohno M., Yano M., Kobayashi S., Doi M., Oda T., Tokuhisa T., et al. A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure. Am J Physiol Heart Circ Physiol 2003, 284(3):H1035-H1042.
52. Yano M., Kobayashi S., Kohno M., Doi M., Tokuhisa T., Okuda S., et al. FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation 2003, 107(January (3)):477-484.
53. Lisy O., Burnett J.C. New cardioprotective agent K201 is natriuretic and glomerular filtration rate enhancing. Circulation 2006, 113(2):246-251.
54. Blayney L.M., Jones J.L., Griffiths J., Lai F.A. A mechanism of ryanodine receptor modulation by FKBP12/12.6, protein kinase A, and K201. Cardiovasc Res 2010, 85(1):68-78.
55. 2+ release in normal adult rabbit ventricular cardiomyocytes. Cardiovasc Res 2007, 76(2):236-246.
56. Couvreur N., Tissier R., Pons S., Chetboul V., Gouni V., Bruneval P., et al. Chronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FKBP12/12.6 expression. Eur Heart J 2009, [Epub ahead of print].
57. Qi M.Y., Xia H.J., Dai D.Z., Dai Y. A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to up-regulation of the expression of FKBP12.6, SERCA2a, and PLB in rats. J Cardiovasc Pharmacol 2006, 47(6):729-735.
58. Park I.Y., Kim E.J., Park H., Fields K., Dunker A.K., Kang C. Interaction between cardiac calsequestrin and drugs with known cardiotoxicity. Mol Pharmacol 2005, 67(1):97-104.
59. Zhou X., Fan G.C., Ren X., Waggoner J.R., Gregory K.N., Chen G., et al. Overexpression of histidine-rich Ca-binding protein protects against ischemia/reperfusion-induced cardiac injury. Cardiovasc Res 2007, 75(3):487-497.
60. Sandrine A., Ferreiro A. Selenoproteins and protection against oxidative stress: selenoprotein N as a novel player at the crossroads of redox signalling and calcium homeostasis. Antioxid Redox Signal 2009, [Epub ahead of print].
61. Jurynec M.J., Xia R., Mackrill J.J., Gunther D., Crawford T., Flanigan K.M., et al. Selenoprotein N is required for ryanodine receptor calcium release channel activity in human and zebrafish muscle. Proc Natl Acad Sci USA 2008, 105(34):12485-12490.
62. Burke B.E., Gambliel H., Olson R.D., Bauer F.K., Cusack B.J. Prevention by dexrazoxane of down-regulation of ryanodine receptor gene expression in anthracycline cardiomyopathy in the rat. Br J Pharmacol 2000, 131(1):1-4.
63. Schmoelzl S., Leeb T., Brinkmeier H., Brem G., Brenig B. Regulation of tissue-specific expression of the skeletal muscle ryanodine receptor gene. J Biol Chem 1996, 271(9):4763-4769.
64. Zhou H., Brockington M., Jungbluth H., Monk D., Stanier P., Sewry C.A., et al. Epigenetic allele silencing unveils recessive RYR1 mutations in core myopathies. Am J Hum Genet 2006, 79(5):859-868.
65. 2+-release channel gene of cardiac sarcoplasmic reticulum. Eur J Biochem 1996, 240(2):408-415.
66. Pfeffer M., Müller C.M., Mordel J., Meissl H., Ansari N., Deller T., et al. The mammalian molecular clockwork controls rhythmic expression of its own input pathway components. J Neurosci 2009, 29(19):6114-6123.
67. Briggs L.E., Takeda M., Cuadra A.E., Wakimoto H., Marks M.H., Walker A.J., et al. Perinatal loss of Nkx2-5 results in rapid conduction and contraction defects. Circ Res 2008, 103(6):580-590.
68. Lewin G., Matus M., Basu A., Frebel K., Rohsbach S.P., Safronenko A., et al. Critical role of transcription factor cyclic AMP response element modulator in beta1-adrenoceptor-mediated cardiac dysfunction. Circulation 2009, 119(1):79-88.
69. 2+ release channel (ryanodine receptor). J Biol Chem 2003, 278(February (7)):4763-4769.
70. Ding J.H., Xu X., Yang D., Chu P.H., Dalton N.D., Ye Z., et al. Dilated cardiomyopathy caused by tissue-specific ablation of SC35 in the heart. EMBO J 2004, 23(4):885-896.
71. 2+ signaling and susceptibility to apoptosis. Circ Res 2007, 100(6):874-883.
72. George C.H., Higgs G.V., Lai F.A. Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes. Circ Res 2003, 93(6):531-540.
73. Song L.S., Sobie E.A., McCulle S., Lederer W.J., Balke C.W., Cheng H. Orphaned ryanodine receptors in the failing heart. Proc Natl Acad Sci USA 2006, 103(11):4305-4310.
74. Jungbluth H., Wallgren-Pettersson C., Laporte J. Centronuclear (myotubular) myopathy. Orphanet J Rare Dis 2008, 3:26.
75. 2+ homeostasis. Nat Cell Biol 2009, 11(6):769-776.